Ultragenyx Pharmaceutical (NASDAQ:RARE) Sees Large Volume Increase Following Analyst Upgrade

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) saw unusually-high trading volume on Friday after Citigroup raised their price target on the stock from $31.00 to $32.00. Citigroup currently has a buy rating on the stock. 2,520,048 shares were traded during mid-day trading, a decline of 3% from the previous session’s volume of 2,590,477 shares.The stock last traded at $14.3060 and had previously closed at $14.50.

RARE has been the topic of a number of other reports. TD Cowen decreased their price objective on Ultragenyx Pharmaceutical from $49.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, September 3rd. Wells Fargo & Company cut Ultragenyx Pharmaceutical from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $50.00 to $18.00 in a research report on Thursday, September 3rd. Evercore downgraded shares of Ultragenyx Pharmaceutical from an “outperform” rating to an “in-line” rating and set a $16.00 price target for the company. in a report on Thursday, September 3rd. Jefferies Financial Group reduced their target price on Ultragenyx Pharmaceutical from $77.00 to $28.00 and set a “buy” rating on the stock in a report on Thursday, September 3rd. Finally, JPMorgan Chase & Co. cut Ultragenyx Pharmaceutical from an “overweight” rating to a “neutral” rating and cut their price target for the company from $80.00 to $36.00 in a report on Thursday, September 3rd. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $37.26.

Ultragenyx Pharmaceutical News Roundup

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: FAYUVI’s approval represents Ultragenyx’s second gene-therapy approval and sixth FDA approval overall. The company expects shipments to qualified treatment centers within 30–60 days and will provide patient-access assistance through its UltraCare program. Ultragenyx Announces Approval of FAYUVI
• Positive Sentiment: Clinical data showed a durable treatment effect and a 23.5-point cognitive-score advantage versus a natural-history cohort, supporting the potential for meaningful clinical benefit. Ultragenyx also received a Priority Review Voucher that could have strategic or financial value. FDA approves Ultragenyx gene therapy
• Positive Sentiment: Canaccord Genuity raised its price target from $37 to $39 and maintained a Buy rating, while Cantor Fitzgerald increased its target from $33 to $39 and assigned an Overweight rating. These revisions indicate improved analyst expectations following the approval.
• Positive Sentiment: The stock’s recent advance occurred on above-average volume, while favorable earnings-estimate revisions may support additional near-term momentum. Ultragenyx stock and earnings estimate revisions
• Neutral Sentiment: Ultragenyx set FAYUVI’s price at $3.95 million, creating substantial revenue potential per patient but also making insurance coverage, reimbursement, and treatment-center access critical to the launch.
• Negative Sentiment: FAYUVI carries important safety risks, including elevated liver enzymes, thrombocytopenia, infusion reactions, and a potential malignancy risk. Long-term commercial adoption and safety remain uncertainties.
• Negative Sentiment: A previously reported failed Angelman syndrome trial and a law-firm investigation into potential investor claims remain overhangs. In addition, reported insider activity consisted entirely of sales over the past six months.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in shares of Ultragenyx Pharmaceutical in the 2nd quarter valued at about $355,746,000. Assenagon Asset Management S.A. raised its stake in Ultragenyx Pharmaceutical by 1,030.4% during the 1st quarter. Assenagon Asset Management S.A. now owns 2,257,671 shares of the biopharmaceutical company’s stock worth $47,298,000 after buying an additional 2,057,951 shares during the period. Norges Bank bought a new position in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at $29,004,000. Bank of America Corp DE purchased a new position in shares of Ultragenyx Pharmaceutical during the second quarter valued at approximately $38,347,000. Finally, Jefferies Financial Group Inc. purchased a new position in Ultragenyx Pharmaceutical during the second quarter worth about $31,040,000. 97.67% of the stock is owned by institutional investors.

Ultragenyx Pharmaceutical Price Performance

The stock has a fifty day moving average of $24.26 and a 200 day moving average of $24.49. The firm has a market capitalization of $1.41 billion, a P/E ratio of -2.45 and a beta of 0.31.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The firm had revenue of $214.00 million for the quarter, compared to analysts’ expectations of $183.08 million. During the same period in the previous year, the company earned ($1.17) earnings per share. The company’s quarterly revenue was up 28.5% on a year-over-year basis. Equities analysts forecast that Ultragenyx Pharmaceutical Inc. will post -3.98 EPS for the current fiscal year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company’s work includes therapies for genetic, metabolic and skeletal disorders, with an emphasis on conditions that have limited or no effective treatment options.

Ultragenyx’s marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Dojolvi (triheptanoin), a medical food for long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab), a treatment for homozygous familial hypercholesterolemia.